BRITISH COLUMBIA, Canada--(BUSINESS WIRE)--InNexus Biotechnology Inc. (OTCBB: IXSBF - News) (TSX VENTURE: IXS - News) (http://www.ixsbio.com), a drug development company commercializing the next generation of monoclonal antibodies based on its technology, Dynamic Cross Linking (DXL™), announced that they will be presenting new in vivo proof of principle data at the American Association for Cancer Research in San Diego, California on April 15, 2008.
